EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kintor Pharmaceutical's enterprise value is HK$351.34 Mil.
Kintor Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,148.47 Mil. Therefore, Kintor Pharmaceutical's EV-to-EBITDA for today is -0.31.
The historical rank and industry rank for Kintor Pharmaceutical's EV-to-EBITDA or its related term are showing as below:
HKSE:09939'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -249.96 Med: -3.95 Max: 0.78
Current: -0.31
During the past 6 years, the highest EV-to-EBITDA of Kintor Pharmaceutical was 0.78. The lowest was -249.96. And the median was -3.95.
HKSE:09939's EV-to-EBITDA is ranked worse than 100% of 451
companies
in the Biotechnology industry
Industry Median: 9.67
vs HKSE:09939: -0.31
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Kintor Pharmaceutical EV-to-EBITDA Historical Data
The historical data trend for Kintor Pharmaceutical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kintor Pharmaceutical's EV-to-EBITDA
For the Biotechnology subindustry, Kintor Pharmaceutical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's EV-to-EBITDA falls into.
Kintor Pharmaceutical's current Enterprise Value is HK$351.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1,148.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kintor Pharmaceutical's PE Ratio for today is calculated as:
Kintor Pharmaceutical's share price for today is HK$1.28.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.702.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Kintor Pharmaceutical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintor Pharmaceutical (HKSE:09939) Business Description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09939 has been successfully added to your 